Where there’s a will, there’s a way. Patients are our will.
1. Partnered collaboration; 2. Acquired; 3. Planned; 4. Jazz & MD Anderson Cancer Center collaboration study; 5. JZP150 is a fatty acid amide hydrolase inhibitor which modulates the endocannabinoid anandamide; 6. HERIZON-BTC-01; 7. Cooperative group study; 8. HERIZON-GEA-01. 1L = first line, 2L = second line, AML = acute myeloid leukemia, COG = Children’s Oncology Group, BTC = biliary tract cancers, CRC = colorectal cancer, DS = Dravet syndrome, EMSCO = European Myelodysplastic Neoplasms Cooperative Group, GEA = gastroesophageal adenocarcinoma, HMA = hypomethylating agents, HR = high-risk, HRD+ = homologous recombinant deficient positive, LGS = Lennox-Gastaut syndrome, MDS = myelodysplastic syndromes, PTSD = post-traumatic stress disorder, R/R = relapsing/refractory, SCLC = small cell lung cancer, SG = study group, TSC = Tuberous sclerosis complex.
Thank you! We'll get back to you shortly.
Please select and enter the required fields on the form below. We need this information to process your request and to take necessary steps to verify your identity.
We will contact you if we need any additional information
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.